The skin is an important target for gene transfer because of its easy accessibility. Using plasmid DNA expressing rat erythropoietin (pCAGGS-Epo) Because of its ready accessibility for direct manipulation and clinical monitoring, the skin is an attractive tissue for gene transfer. Direct in vivo plasmid DNA transfer to the skin via injection 1,2 and topical administration 3 have been reported. Intradermally injected plasmid DNA rapidly traverses the dermo-epidermal junction and is taken up and expressed by keratinocytes in the epidermis. 4 Active transgene expression in the epidermis is lost by 3 days after injection, 1 a time period that is too short for clinical applications. Moreover, skin takes up and expresses DNA less efficiently than does muscle.
Because of its ready accessibility for direct manipulation and clinical monitoring, the skin is an attractive tissue for gene transfer. Direct in vivo plasmid DNA transfer to the skin via injection 1, 2 and topical administration 3 have been reported. Intradermally injected plasmid DNA rapidly traverses the dermo-epidermal junction and is taken up and expressed by keratinocytes in the epidermis. 4 Active transgene expression in the epidermis is lost by 3 days after injection, 1 a time period that is too short for clinical applications. Moreover, skin takes up and expresses DNA less efficiently than does muscle. 5 Consequently, skin-targeted transfer of plasmid DNA has focused on two principal therapeutic uses: genetic immunization 6, 7 and the expression of biological response modifiers to treat skin disease. 4 Gene gun 8, 9 and jet injection 10 techniques have been developed for effective skin-targeted gene transfer. A gene gun technique has been used to successfully deliver naked DNA into the epidermis. 11 Klinman et al 11 also reported that, compared with muscle, skin is a suitable site for the short-term (3 weeks) production of erythropoietin (Epo), due to the rapid turnover of skin cells. Skin-targeted gene transfer by in vivo electroporation has been shown to be effective for introducing plasmid DNA, including the SV40 T antigen gene, into newborn mouse skin, 12 and the lacZ gene has been transferred into the hairless mouse with skin-depth targeting. 13 However, there are no reports on the systemic delivery of therapeutic proteins by skin-targeted gene transfer using electroporation. We demonstrate here that skin-targeted transfer of the Epo gene using electroporation with plate-and-fork-type electrodes produced physiologically significant levels of Epo in the systemic circulation for 7 weeks, and increased erythropoiesis in normal rats for 11 weeks.
We tested three types of electrodes for skin-targeted gene transfer (Figure 1 ). To optimize the voltage of the electric pulses used for in vivo electroporation, we compared the serum Epo levels of rats subjected to electroporation at various voltages that did not cause macroscopic skin damage: 50 V, 24 V and 12 V, for the needletype electrodes, and 24 V, 18 V and 12 V, for the disktype and plate-and-fork-type electrodes. Pre-and postinjection serum Epo levels were measured on day Ϫ7 before and day 7 after intradermal injection with 800 g of either pCAGGS-Epo or pCAGGS. Only electroporation with the plate-and-fork-type electrodes at low voltages significantly increased the serum Epo levels ( Figure 2 ). This result demonstrates that the type of electrode used is of critical importance in skin-targeted Epo gene transfer using in vivo electroporation. The difference in effectiveness of electrode types is probably explained by differences in the direction of the current to the skin. With the needle-type electrodes, the current travels horizontally within the skin between the electrodes. With the disk-type electrodes, which have uneven surfaces, the current travels in random directions. In contrast, with the plate-and-fork-type electrodes, the current crosses the skin vertically.
Using our experimental conditions, the electroporation did not cause any macroscopic skin damage, such as burns or edema, throughout the experimental period. Histological analysis of skin damage due to gene transfer was performed on days 1 ( Figure 3 ) and 7 after in vivo electroporation. Injection of pCAGGS-Epo or PBS alone without electroporation caused a mild mononuclear infiltration in the dermo-epidermal junction, dermis, and subcutaneous fat (Figure 3b ). When electroporation was performed without DNA injection, acanthosis was observed at 24 V (Figure 3c ). Injection of pCAGGS-Epo followed by electroporation at 24 V caused the skin damage shown in Figure 3d , acanthosis, hyperkeratosis with parakeratosis in the horny layer, and a mild mononuclear infiltration. The skin damage caused by electroporation at 12 or 18 V was less than that at 24 V (data not shown). This damage could explain why electroporation at lower voltages resulted in more effective gene transfer. Therefore, in subsequent experiments, we conducted electroporation with the plate-and-fork-type electrodes at 18 V. The skin damage seen on day 1 disappeared by day 7 after electroporation (data not shown).
Although intradermal injection involved the physical targeting of naked DNA to the skin, no other feature of the technique ensured that the expression of the injected DNA would be skin-specific. It was important to evaluate, therefore, whether the transgene was localized to and expressed only in the injected skin. Using RT-PCR, we detected the transgene-derived Epo mRNA only in the skin injected with pCAGGS-Epo, but not in that injected with pCAGGS (Figure 4 upper panel) , while we detected control glyceraldehyde 3-phosphate dehydrogenase (G3PDH) mRNA in the skin of all injected rats (Figure 4  lower panel) .
A dose-response relationship between the amount of injected pCAGGS-Epo and the serum Epo levels was observed (Figure 5a ). After intradermal injection with 1600 g of pCAGGS-Epo followed by electroporation, 
Figure 3 Histological analysis of skin damage caused by gene transfer. We harvested the skins on day 1 after gene transfer, fixed them in 10% buffered formaldehyde, embedded them in paraffin, and processed them for routine light microscopy. We then stained 5-m sections with hematoxylin and eosin for the detection of possible tissue injury due to the gene transfer procedure. Hematoxylin and eosin-stained sections of skin that was not electroporated and either was not (a) or was (b) injected with pCAGGS-Epo, and of skin electroporated using plate-and-fork-type electrodes at 24 V without (c) or with pCAGGS-Epo injection (d). Original magnification ×150.

Figure 4 RT-PCR detection of Epo mRNA in major organs after intradermal injection of pCAGGS-Epo or pCAGGS with electroporation using plate-and-fork type electrodes at 18 V. Four days after injection, rats that had received 800 g of either pCAGGS-Epo (n = 1) or pCAGGS (n =
1
Figure 5 Effects of Epo gene transfer by intradermal electroporation. (a) Serum Epo levels; (b) reticulocyte levels; (c) hematocrit levels. Differences between groups were tested by unpaired t tests.
* P Ͻ 0.05, * * P Ͻ 0.01 and * * * P Ͻ 0.001 for comparisons with the control rats (comparisons were made within each time-point). Muscle-targeted gene transfer by in vivo electroporation was performed essentially as previously described. 14 A total of 200 g of plasmid DNA was injected into the lateral sides of both lower legs (100 g/each site). Hematocrit and reticulocytes levels were determined as previously described. 14 serum Epo levels peaked at 35.5 ± 0.9 mU/ml at week 1, and gradually decreased with slight fluctuations; however, they remained more elevated at each time-point tested after DNA injection than did those of the rats given lower doses of the gene. Although skin-targeted gene transfer is less efficient than muscle-targeted gene transfer, these data indicate that skin-targeted gene transfer using in vivo electroporation can elicit the continuous delivery of Epo for 7 weeks in rats. Vector-derived Epo secretion caused detectable reticulocytosis at week 1 (Figure 5b ). The number of reticulocytes significantly increased in rats injected with 800 g or more, followed by in vivo electroporation. In addition, the hematocrit levels of the rat groups injected with 800 g or more were significantly elevated after gene transfer (Figure 5c ). After intradermal injection with 1600 g of pCAGGS-Epo followed by electroporation, the hematocrit levels increased for 11 weeks. Thus, skin-targeted pCAGGS-Epo plasmid transfer by in vivo electroporation continuously produced biologically active Epo, resulting in a significant elevation in the number of reticulocytes and the hematocrit, in a dose-dependent manner.
To clarify the location and time-course of transgene expression after skin-targeted gene transfer, we performed a histochemical analysis of skin into which pCAGGS-lacZ was introduced by in vivo electroporation with plate-and-fork-type electrodes. ␤-Galactosidase was expressed in the upper most cell layers (horny, granular and prickle cell layers) of the epidermis on day 1 and in the subcutaneous muscle layer on day 7 after the pCAGGS-lacZ transfer ( Figure 6 ). Gene expression in the epidermis and the dermis continued for less than 7 days, as reported previously. 1 The gene transfer into the subcutaneous muscle layer could explain why Epo secretion continued for more than 3 weeks, considering the rapid Gene Therapy turnover of epidermal cells. Intradermal injection of pCAGGS-lacZ without subsequent electroporation did not result in the expression of detectable ␤-galactosidase.
In a previous report, the epidermal delivery of an Epoencoding plasmid by gene gun resulted in the dosedependent secretion of Epo for less than 1 month.
11 Such short-term gene expression may be most suitable for optimizing Epo production by subsequent readministrations. A general rule of gene therapy is that the duration of gene expression should not be longer than that of the target diseases. Hence, skin-targeted gene transfer may be suitable not only for chronic diseases but also for acute diseases requiring the short-term systemic delivery of a therapeutic protein. A good example of such a disease is systemic inflammatory response syndrome. As shown in Figure 5 and in our previous report, 14 muscle-targeted gene transfer is capable of bringing about long-term and strong gene expression, compared with skin-targeted gene transfer. Considering the characteristics of these candidate target tissues for gene transfer, we can now plan therapies using both muscle-and skin-targeted gene transfer strategies. For example, we could supply the minimum amount of Epo needed to correct anemia by muscle-targeted gene transfer, and supplement any shortage by skin-targeted gene transfer. Skin-targeted gene transfer may be used for the treatment of patients requiring higher doses of Epo due to a hyporesponsiveness to Epo that can occur as a result of various conditions, including inflammation, infection, malignancy and pregnancy, and which subsides soon after recovery.
Hyporesponsiveness to Epo resolves when the underlying disorder is treated successfully, and it is rare for any additional therapy to be required.
